What Cambridge Cognition does

Cambridge Cognition is a UK-headquartered neuroscience technology company that builds digital and voice-based cognitive assessment software for CNS clinical trials, academic research, and healthcare. Its flagship platform, CANTAB (Cambridge Neuropsychological Test Automated Battery), originated at the University of Cambridge in 1984 and was spun out into the company in 2002; the company listed on the AIM market of the London Stock Exchange in 2013 under ticker COG. The core offering combines scientifically validated touchscreen cognitive tests covering attention, executive function, memory, and social cognition, with voice-based assessments acquired via Winterlight Labs in January 2023 (rebranded NeuroVocalix) and an automated quality assurance module (AQUA) for CNS clinical scales.

The product portfolio is organised around a platform-plus-modules architecture: CANTAB Connect Research serves 800+ academic institutions, Clinpal (acquired via eClinical Health in 2022) provides decentralised clinical trial infrastructure, eCOA delivers electronic questionnaires and scales, Cognition Kit enables high-frequency mobile testing, and CANTAB Mobile/Insight/BrainHealth address primary care, secondary care, and workplace wellness respectively. CANTAB Pathway, launched in 2026, extends the platform into consumer and healthcare screening. The company serves the world's top 20 pharmaceutical companies alongside academic and healthcare customers across 100+ countries.

Commercially, revenue is generated primarily through subscription-based enterprise contracts for clinical trial services, with most of the £9.4 million revenue derived from clinical studies. Pricing is quote-based and undisclosed publicly. Go-to-market is sales-led across enterprise pharma, academic, and healthcare channels, supplemented by strategic channel partnerships (e.g., Ivory for India) and academic/government validation work. The company is loss-making and is reinvesting behind a November 2025 leadership transition, an India expansion, and a consumer-oriented product push via CANTAB Pathway and the Oura wearable collaboration.

Name

Cambridge Cognition

Legal name

Cambridge Cognition Ltd

Website

https://cambridgecognition.com

Company type

Public

Founded year

2002

Operating status

Operating

Headcount range

51–100 employees

Short description

Cambridge Cognition is a UK-listed neuroscience technology company that provides digital and voice-based cognitive assessment software for CNS clinical trials, academic research, and healthcare, serving the world's top 20 pharmaceutical companies and 800+ academic institutions.

Ownership category

akta.pro rank

Product category

Cognitive Assessment Software

NAICS

Scientific Research and Development Services (5417), Professional, Scientific, and Technical Services (54)

SIC

Services-Health Services (8000), Services-Commercial Physical & Biological Research (8731)

akta.pro primary industry

Behavioral Health & Neurocognitive Therapeutics (Digital) (HLACANAI)

akta.pro secondary industry

Neurodevelopmental & Behavioral Therapy Platforms (ADHD/Autism/Behavioral Coaching) (HLALAEAJ)

Keywords

• Cognitive assessment software
• Clinical trial technology
• Digital cognitive testing
• Voice biomarker analysis
• Decentralised clinical trials

Headquarters

HQ city

Bottisham

HQ country

United Kingdom

HQ region

Europe

Offices3 records

Markets served

GTM type

B2B

Offering type

Software

Cost components

Personnel, Technology or R&D, Marketing or Sales, Operations, Infrastructure

Revenue model

1. Clinical Trial Services: Revenue from pharmaceutical companies for cognitive assessment services in clinical trials. Most of the company's £9.4 million revenue comes from clinical studies. Services include touchscreen assessments, voice analysis, eCOA, and DCT platform services.
2. Software Licensing: Licensing of CANTAB cognitive assessment software to pharmaceutical companies, academic institutions, and healthcare providers. Platform accessed via iPad, web browser, and mobile devices with subscription-based access.
3. Academic Research Subscriptions: CANTAB Connect Research platform licensed to universities and research institutions with departmental license options for multiple projects.
4. Healthcare Solutions: CANTAB Mobile, CANTAB Insight, and CANTAB BrainHealth products for healthcare settings including primary care, secondary care, and workplace wellness applications.

Pricing tiers

Go-to-market motion5 records

Distribution channels4 records

Marketing channels6 records

Core offering

Cambridge Cognition develops and licenses the CANTAB digital cognitive assessment platform and related neuroscience technologies for pharmaceutical clinical trials, academic research, and healthcare providers. Its portfolio includes touchscreen cognitive assessments, voice-based speech biomarker analysis (NeuroVocalix), electronic clinical outcome assessments (eCOA), automated quality assurance (AQUA), and the Clinpal decentralised clinical trials platform, deployed in over 100 countries and validated across 250+ therapeutic indications.

Product overview

Cambridge Cognition offers a unified platform-plus-modules architecture centered on CANTAB®, the world's most validated cognitive assessment software. The core CANTAB® platform provides touchscreen-based digital cognitive assessments validated in over 3,000 publications across 250+ indications. Supporting modules include: CANTAB Connect Research™ for academic institutions, CANTAB Connect™ for unified assessment management, and Clinpal for decentralized clinical trials. Voice-based assessment capabilities are delivered through Winterlight Labs/NeuroVocalix® technology. Healthcare products include CANTAB Mobile, CANTAB Insight, and CANTAB BrainHealth for different care settings. CANTAB Pathway™ extends reach into consumer markets. Additional modules include AQUA for automated quality assurance, eCOA for electronic questionnaires, Cognition Kit™ for wearable device testing, and Speaker Identification for trial integrity.

Differentiator

Problem solved

Functional benefit

Brands

• CANTAB: World's most validated cognitive assessment software, recognized as an international gold standard for digital cognitive testing, used in over 3,000 peer-reviewed publications.
• NeuroVocalix
• Clinpal
• AQUA
• Cognition Kit

Products and services

• CANTAB World's most validated digital cognitive assessment software, delivering highly sensitive, scientifically validated touchscreen tests covering attention, psychomotor speed, executive function, emotion/social cognition, and memory. Validated in over 3,000 peer-reviewed publications across 250+ therapeutic indications. Used by the world's top 20 pharmaceutical companies and 800+ academic institutions.
• CANTAB Connect Unified platform for managing and delivering touchscreen and voice assessments along with customizable electronic questionnaires and scales, providing secure, scalable, cost-effective cognitive assessment delivery.
• CANTAB Connect Research Cloud-based research platform for academic institutions providing validated, precise, and reliable cognitive assessment technology. Trusted by 800+ world-leading universities, with real-time data access via web browser and ISO 27001 compliance.
• CANTAB Mobile Tablet-based cognitive assessment tool for healthcare settings, specifically developed for rapid and sensitive memory assessments in primary care with an average completion time of 10 minutes.
• CANTAB Insight Cognitive health assessment tool for secondary care that supports differential diagnosis and informs diagnostic process and care planning, with an average completion time of 20–30 minutes.
• CANTAB BrainHealth Workplace wellbeing assessment using clinically validated mental health scales to measure employee wellbeing, enabling health professionals to provide actionable next steps.
• CANTAB Pathway Digital cognitive assessment product for consumer and healthcare settings providing a trusted journey from screening to understanding and monitoring brain health, available in multiple languages for global deployment including India.
• Voice Analysis / NeuroVocalix Voice-based cognitive assessment platform that analyses verbal tasks to assess cognitive domains not examinable by visual tasks alone, using automated speech recognition with up to 98% accuracy. Includes Category Fluency, Letter Fluency, Diadochokinetic Rate, Journalling, Paragraph Reading/Recall, Picture Description, and Sustained Phonation.
• Cognition Kit High-frequency cognitive testing solution for wearable devices and mobile phones, detecting changes in day-to-day cognition through short regular tests using patients' own devices. Includes Psychomotor Vigilance Task, Digit Symbol Substitution, Emotional Bias Task, and N-Back tests.
• AQUA AI-powered Automated Quality Assurance system for clinical scales. Analyses audio during administration of CNS clinical scales (ADAS-Cog, HAM-A, MADRS, CDR, HAM-D, PANSS) in 8 languages to detect deviations in administration and scoring, reducing quality review costs by up to 60%.
• eCOA (Electronic Clinical Outcome Assessments) Digital administration of bespoke questionnaires and universally recognised clinical scales, capturing high-quality neurocognitive data across multiple devices with online and offline capability, multilingual support, and full audit trail.
• Clinpal Decentralised Clinical Trials (DCT) platform for patient-centric, clinician-focused, sponsor-efficient virtual, hybrid and direct-to-patient studies. Modules include informed consent, recruitment, eCOA, EDC, telemedicine, and data archiving, with API integration for third-party devices and assessments.
• Speaker Identification Solution Voice-based speaker verification solution that safeguards clinical trial integrity by ensuring correct participant identity during assessments.

Quantifiable outcome

• 95% patient engagement rate in clinical trials using Cambridge Cognition technology
• +4 more outcomes

Named customers6 records

Segments3 records

Ideal customer profiles3 records

Technology focussed Yes

API detail

Has API

Yes

API docs

API detail

Core technology

AI maturity

App detail

AI capability3 records

Feature7 records

Partnerships

Six partnerships are on record, tiered core, flagship, minor and competitive.

• OuracoreStrategic or Co-development Partner · 28 May 2026Collaboration to conduct an institutional review board-approved brain health study integrating Cambridge Cognition's cognitive assessments with Oura Ring wearable physiological data. The observational research program includes up to 45,000 Oura members who complete brief cognitive assessments through the Oura app while the device monitors sleep, activity, stress, and physiological measurements. Study runs through 2026.
• IvoryflagshipChannel Partner/ Reseller/ Distributor · 17 February 2026Strategic partnership to commercialize CANTAB Pathway digital cognitive assessment products across healthcare and consumer health markets in India. Ivory will deploy assessments at scale across professional and consumer segments using its established clinical network. Products already available in multiple Indian languages including Hindi, Tamil, Telugu, Bengali, and Kannada. Partnership addresses India's estimated 34 million people with mild or major cognitive impairment among those aged over 60.
• Monument TherapeuticsminorStrategic or Co-development Partner · 27 June 2024Cambridge Cognition holds an investment in Monument Therapeutics, a company developing novel treatments for schizophrenia. Monument achieved positive Phase I results for a novel schizophrenia treatment. Also partnered with Foundation for the National Institutes of Health for clinical trial of MT1988.
• Winterlight LabscoreOEM/ Whitelabel/ Licensing Partner · 11 January 2023Acquired Winterlight Labs for £7.0 million (cash payment and shares) to enhance Cambridge Cognition's voice-based assessment capabilities. The acquisition focused on cognitive impairment monitoring through speech analysis technology. Winterlight Labs was founded in Toronto in 2015 by Frank Rudzicz, Katie Fraser, Liam Kaufman and Maria Yancheva. Combined entity leads in voice and digital biomarkers for clinical trials.
• eClinical HealthcoreOEM/ Whitelabel/ Licensing Partner · 1 January 2022Acquired eClinical Health to extend virtual clinical trial solutions including remote patient monitoring, electronic informed consent, and online data capture through the Clinpal DCT platform. This acquisition enabled end-to-end decentralised clinical trial capabilities.
• Pearson Clinical AssessmentcompetitiveStrategic or Co-development PartnerIdentified as primary competitor along with CogniFit and CogniSense in cognitive assessment market research reports. Cambridge Cognition competes directly with Pearson for pharmaceutical, academic, and healthcare cognitive assessment contracts.

Scale indicators12 records

Recent moves7 records

Expansion highlights6 records

Emerging players

• Cumulus Neuroscience: Cumulus Neuroscience is an emerging digital biomarker platform that combines cognitive testing with physiological and digital phenotyping for CNS clinical trials. It overlaps with Cambridge Cognition's high-frequency cognition kit and DCT efforts but takes a more multimodal device-centric approach.
• Linus Health: Linus Health provides digital cognitive assessment (e.g., DCTclock) for early detection of cognitive impairment in clinical and research settings. It is comparable in its digital cognitive assessment focus but concentrates on the primary care and health system channels rather than pharma clinical trials.
• Neurotrack Technologies: Neurotrack offers digital cognitive assessment tools for early detection and monitoring of cognitive decline, including a 10-minute online test. It overlaps with Cambridge Cognition's healthcare-facing CANTAB Mobile and CANTAB Insight but does not serve the pharma clinical trial market.
• Posit Science (BrainHQ): Posit Science develops computerized cognitive training and assessment tools with clinical evidence, including FDA-cleared programs. It is comparable in using validated digital cognitive science, but its commercial model emphasizes consumer/clinical training rather than clinical trial endpoints.

Broad incumbents

• Medidata Solutions (Dassault Systèmes): Medidata offers the Rave eCOA platform and broader clinical trial suite. It is a broad incumbent whose eCOA offerings overlap with Cambridge Cognition's electronic clinical outcome assessments and decentralized trial capabilities, even though it does not specialize in cognitive endpoints.
• Clario (formerly ERT / Bioclinica): Clario is a large-scale clinical trial technology vendor offering eCOA, imaging, and digital endpoints. It overlaps with Cambridge Cognition in CNS clinical scales administration and eCOA but competes as part of a much broader portfolio rather than specializing in cognitive assessment.
• Pearson Clinical Assessment: Pearson Clinical Assessment is explicitly identified as a primary competitor of Cambridge Cognition in cognitive assessment for pharma, academic, and healthcare customers. As a division of a much larger publishing/education conglomerate, it competes on breadth and established relationships rather than scientific novelty.

Direct peers

• Cogstate: Cogstate is the closest direct peer — both companies offer validated computerized cognitive assessment batteries for CNS clinical trials and academic research, competing for the same pharma R&D budgets and academic licensing deals. Cogstate is publicly listed on the ASX and serves most of the same top-20 pharmaceutical clients.
• CogniFit: CogniFit offers computerized cognitive assessment and brain training for both consumer and clinical/professional markets. It is identified as a competitor to Cambridge Cognition in cognitive assessment, though it tilts more toward consumer and brain training than regulatory-grade clinical trial endpoints.
• Medavante (WCG Clinical Services): Medavante-ProPhase (now part of WCG) provides CNS clinical ratings, eCOA, and rater training services used in psychiatric and neurological clinical trials. It directly competes with Cambridge Cognition's eCOA and CNS scale administration offerings for the same pharma sponsors.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

• Xx.com/cantabconnect
• Facebookfacebook.com/cantabconnect
• LinkedInlinkedin.com/company/cambridge-cognition

Compliance1 record

Revenue estimate

Valuation estimate

Number of profiles

Profiles9 records

Subsidiaries1 record

Funding overview

Funding rounds6 records

Investors1 record

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A2 records

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Cambridge Cognition